Introduction Guidelines recommend respiratory fluoroquinolone monotherapy or β-lactam
plus macrolide combination therapy as first-line options for hospitalized adults with mild to …

Background: The choice of empirical antibiotic treatment for patients with community-
acquired pneumonia (CAP) who are admitted to non-intensive care unit (ICU) hospital wards …

Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality. This
review compared two of the main treatment alternatives: quinolone or macrolide …

Background: We investigated whether the use of respiratory fluoroquinolones was
associated with better clinical outcomes compared with the use of macrolides and β-lactams …

Objective The best treatment option for hospitalized patients with community-acquired
pneumonia (CAP) has not been defined. The effectiveness of β-lactam/fluoroquinolone …

Background The majority of community-acquired pneumonia (CAP) patients (about 80%)
will be treated as outpatients, because therapy with a single agent will work. For the …

OBJECTIVE: To determine the role of newer fluoroquinolones (FQs) for adults with
community-acquired pneumonia (CAP) whose level of illness allows treatment with an oral …

The aim of this study was to compare more conclusively the efficacy and safety of
moxifloxacin, a new respiratory fluoroquinolone antibiotic, with β-lactam-based standard …

Background The goal of this study was to investigate whether ceftriaxone combination
therapy is associated with better clinical outcomes than respiratory fluoroquinolone …

Background. Macrolides are used to treat pneumonia despite increasing antimicrobial
resistance. However, the immunomodulatory properties of macrolides may have a favorable …